メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
日比 八束
医学部・内分泌外科
h-index
686
被引用数
13
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1995 …
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(32)
類似のプロファイル
(6)
フィンガープリント
Yatsuka Hibiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Adrenal Disease
29%
Adrenalectomy
29%
Anaplastic Thyroid Carcinoma
31%
Asymptomatic Carrier
29%
Autograft
36%
Breast Cancer
29%
Calcitonin
43%
Cell Hyperplasia
11%
Computer Assisted Tomography
14%
Cyclic AMP Dependent Protein Kinase 1
29%
Disease
31%
Echography
48%
Focal Nodular Hyperplasia
33%
Glomerular Filtration Rate
25%
Hirschsprung's Disease
14%
Hyperparathyroidism
87%
Incidentaloma
29%
Incisional Hernia
29%
Inferior Vena Cava
29%
Kidney Dysfunction
10%
Kidney Function
29%
Lenvatinib
29%
Liver Tumor
29%
Lymph Node
14%
Lymph Node Metastasis
19%
Magnetic Resonance Imaging
14%
Malignant Neoplasm
9%
Multiple Endocrine Neoplasia Type 2a
29%
Neck
16%
Neoplasm
18%
Papillary Thyroid Cancer
29%
Parathyroid
20%
Parathyroid Gland
100%
Parathyroid Hormone
26%
Parathyroidectomy
71%
Pheochromocytoma
14%
Polystyrenesulfonate Calcium
11%
Primary Hyperaldosteronism
58%
Primary Hyperparathyroidism
29%
Programmed Cell Death
14%
Renal Agenesis
14%
Reoperation
79%
Retroperitoneal Lymph Node Dissection
26%
Scintigraphy
14%
Secondary Hyperparathyroidism
32%
Solitary Kidney
29%
Stomach Cancer
29%
Thyroid Medullary Carcinoma
13%
Thyroidectomy
36%
Tumor Invasion
20%
Keyphrases
7,12-dimethylbenz(a)anthracene
29%
Adrenal Disease
29%
Anaplastic Thyroid Cancer
31%
Asymptomatic Carriers
29%
BRAF V600E
29%
Calcium Polysulfide
11%
Carcinoma Thyroid
10%
Combination Therapy
29%
Corticotropin
29%
Dabrafenib Plus Trametinib
29%
Dimethylbenz(a)anthracene
9%
Extra-adrenal Pheochromocytoma
14%
Follicular Cancer
29%
Hirschsprung Disease
14%
Hormone Concentration
12%
Hypercalcitoninemia
29%
Incidentaloma
29%
Incisional Hernia
29%
Inferior Vena Cava Syndrome
29%
Intact Parathyroid Hormone (iPTH)
12%
Intracaval
16%
Jelly
11%
Laparoscopic Adrenalectomy
29%
Limited Operation
29%
Mesh Plug Repair
29%
Mucosal Gastric Cancer
14%
Nodular Hyperplasia
29%
Papillary Thyroid Carcinoma
21%
Parathyroid Glands
29%
Parathyroid Tissue
11%
Parathyroidectomy
29%
PAX8
29%
Persistent Hyperparathyroidism
18%
Primary Aldosteronism
29%
Primary Hyperparathyroidism (pHPT)
29%
Recurrent Hyperparathyroidism
18%
Renal Agenesis
14%
Renal Hyperparathyroidism
29%
Reoperation
29%
RET mutation
29%
Secondary Hyperparathyroidism
29%
Serum Calcitonin
12%
Single-center Retrospective Study
29%
Thyroid Cancer
29%
Thyroid Disorders
29%
Unilateral Adrenalectomy
29%
Unilateral Renal Agenesis
29%
Uremic Patients
29%
Wakame Seaweed
29%
Zona Glomerulosa
9%
Pharmacology, Toxicology and Pharmaceutical Science
7,12-Dimethylbenz(a)anthracene
29%
Anaplastic Thyroid Carcinoma
60%
Breast Cancer
29%
Carcinogenesis
8%
Clinical Trial
7%
Combination Therapy
38%
Cyclic AMP Dependent Protein Kinase 1
29%
Dabrafenib
29%
Disease
29%
Disease Course
9%
Glial Cell Line Derived Neurotrophic Factor
7%
Goiter
7%
Hirschsprung's Disease
14%
Kidney Agenesis
14%
Lenvatinib
32%
Lymph Node Metastasis
19%
Malignant Neoplasm
9%
Multiple Endocrine Neoplasia Type 2a
29%
Neoplasm
18%
Nodular Hyperplasia
29%
Overall Survival
13%
Parathyroid Hormone
29%
Pheochromocytoma
14%
Progression Free Survival
8%
Retrospective Study
29%
Secondary Hyperparathyroidism
29%
Solitary Kidney
29%
Stomach Cancer
29%
Thyroglobulin
29%
Thyroid Cancer
29%
Thyroid Medullary Carcinoma
7%
Thyroid Papillary Carcinoma
21%
Trametinib
29%
Undaria
33%
